<p>在最近三个月中，6 位分析师对 Solventum（纽约证券交易所代码：SOLV）进行了评估，表达了看涨和看跌的不同观点。</p>
<p>下表提供了他们最近评级的快速概览，突显了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师对 12 个月价格目标的评估提供了额外的见解，显示出平均目标为 96.5 美元，最高估计为 105.00 美元，最低估计为 79.00 美元。这一上升趋势显而易见，目前的平均值较之前的 86.00 美元的平均价格目标增加了 12.21%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769428838_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769428838_0.png"/></p>
<h2>解读分析师评级：深入分析</h2>
<p>对近期分析师行动的分析揭示了金融专家对 Solventum 的看法。以下总结展示了主要分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>宣布</td>
<td>超配</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上调</td>
<td>表现优于大盘</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>上调</td>
<td>买入</td>
<td>$105.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>宣布</td>
<td>买入</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上调</td>
<td>中性</td>
<td>$79.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$98.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 针对市场动态和公司表现的变化，分析师更新了他们的建议。无论是 ‘维持’，‘上调’ 还是 ‘下调’ 他们的立场，都表明他们对 Solventum 近期发展的反应。这为分析师对公司当前状态的看法提供了见解。</li>
<li><strong>评级：</strong> 通过揭示见解，分析师提供了对股票表现的定性见解，从 ‘表现优于大盘’ 到 ‘表现不及大盘’。这些评级传达了对 Solventum 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 分析师提供了对价格目标的见解，给出了对 Solventum 股票未来价值的估计。这一比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>将这些分析师评估与相关财务指标进行分析，可以提供对 Solventum 市场地位的全面视角。保持信息灵通，并借助我们的评级表做出数据驱动的决策。</p>
<p>随时了解 Solventum 分析师评级。</p>
<h2>深入了解 Solventum 的背景</h2>
<p>在 2024 年春季，3M 将其传统医疗保健部门剥离为独立公司 Solventum。当时，该公司由四个部门组成。最小的一个——净化和过滤部门——已经被出售。现在，医疗外科是最大的业务，约占合并收入的 64%，包括先进的伤口护理和伤口预防。牙科解决方案（修复复合材料和正畸）和健康信息系统（主要是收入周期管理）各占总收入的 18%。</p>
<h3>Solventum：财务概览</h3>
<p><strong>市值分析：</strong> 该公司的市值超过行业平均水平，展示了相对于同行的主导地位，暗示了强大的市场地位。</p>
<p><strong>收入增长：</strong> Solventum 在 3M 的卓越表现显而易见。截至 2025 年 9 月 30 日，该公司实现了 <strong>0.67%</strong> 的显著收入增长率。这标志着公司营业收入的显著增加。与医疗保健行业的其他公司相比，该公司面临挑战，增长率低于同行的平均水平。</p>
<p><strong>净利润率：</strong> 该公司的净利润率表现突出，超过行业平均水平。凭借 <strong>60.4%</strong> 的净利润率，该公司展示了强大的盈利能力和有效的成本控制。</p>
<p><strong>股本回报率（ROE）：</strong> 该公司的 ROE 表现突出，超过行业平均水平。凭借 <strong>29.34%</strong> 的 ROE，该公司展示了有效利用股本的能力。</p>
<p><strong>资产回报率（ROA）：</strong> Solventum 的财务实力体现在其卓越的 ROA 上，超过行业平均水平。凭借 <strong>8.72%</strong> 的 ROA，该公司展示了资产的高效使用和强大的财务健康。</p>
<p><strong>债务管理：</strong> Solventum 的债务与股本比率低于平均水平，为 <strong>1.03</strong>，采取了谨慎的财务策略，表明了对债务管理的平衡方法。</p>
<h2>分析师评级的重要性解释</h2>
<p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
<p>分析师可能会补充他们的评级，预测增长估计、收益和收入等指标，为投资者提供更全面的前景。然而，投资者应注意，分析师和任何人一样，可能会受到主观观点的影响，从而影响他们的预测。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

医疗业 ETF - SPDR

SOLV

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

3M公司

<p>分析师在过去三个月对 Solventum（纽约证券交易所代码：SOLV）提供了不同的评估，共有 6 位分析师对该股票进行了评级。12 个月的平均目标价为 96.5 美元，较之前的目标上涨了 12.21%。主要分析师提高了他们的评级，目标价范围在 79.00 美元到 105.00 美元之间。Solventum 是从 3M 分拆出来的公司，财务表现强劲，净利润率为 60.4%，股本回报率为 29.34%。该公司保持谨慎的债务管理策略，债务与股本比率为 1.03</p>

<p>6 analysts have shared their evaluations of Solventum (NYSE: SOLV) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最近三个月中，6 位分析师对 Solventum（纽约证券交易所代码：SOLV）进行了评估，表达了看涨和看跌的不同观点。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的快速概览，突显了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $96.5, with a high estimate of $105.00 and a low estimate of $79.00. This upward trend is evident, with the current average reflecting a 12.21% increase from the previous average price target of $86.00.</p>
<div class="lb-trans"><p>分析师对 12 个月价格目标的评估提供了额外的见解，显示出平均目标为 96.5 美元，最高估计为 105.00 美元，最低估计为 79.00 美元。这一上升趋势显而易见，目前的平均值较之前的 86.00 美元的平均价格目标增加了 12.21%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769428838_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769428838_0.png"/></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<div class="lb-trans"><h2>解读分析师评级：深入分析</h2>
</div><p>The analysis of recent analyst actions sheds light on the perception of Solventum by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>对近期分析师行动的分析揭示了金融专家对 Solventum 的看法。以下总结展示了主要分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>宣布</td>
<td>超配</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上调</td>
<td>表现优于大盘</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>上调</td>
<td>买入</td>
<td>$105.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>宣布</td>
<td>买入</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上调</td>
<td>中性</td>
<td>$79.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$98.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Solventum. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Solventum compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Solventum's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 针对市场动态和公司表现的变化，分析师更新了他们的建议。无论是 ‘维持’，‘上调’ 还是 ‘下调’ 他们的立场，都表明他们对 Solventum 近期发展的反应。这为分析师对公司当前状态的看法提供了见解。</li>
<li><strong>评级：</strong> 通过揭示见解，分析师提供了对股票表现的定性见解，从 ‘表现优于大盘’ 到 ‘表现不及大盘’。这些评级传达了对 Solventum 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 分析师提供了对价格目标的见解，给出了对 Solventum 股票未来价值的估计。这一比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Solventum's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>将这些分析师评估与相关财务指标进行分析，可以提供对 Solventum 市场地位的全面视角。保持信息灵通，并借助我们的评级表做出数据驱动的决策。</p>
</div><p>Stay up to date on Solventum analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Solventum 分析师评级。</p>
</div><h2>Delving into Solventum's Background</h2>
<div class="lb-trans"><h2>深入了解 Solventum 的背景</h2>
</div><p>In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.</p>
<div class="lb-trans"><p>在 2024 年春季，3M 将其传统医疗保健部门剥离为独立公司 Solventum。当时，该公司由四个部门组成。最小的一个——净化和过滤部门——已经被出售。现在，医疗外科是最大的业务，约占合并收入的 64%，包括先进的伤口护理和伤口预防。牙科解决方案（修复复合材料和正畸）和健康信息系统（主要是收入周期管理）各占总收入的 18%。</p>
</div><h3>Solventum: A Financial Overview</h3>
<div class="lb-trans"><h3>Solventum：财务概览</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值超过行业平均水平，展示了相对于同行的主导地位，暗示了强大的市场地位。</p>
</div><p><strong>Revenue Growth:</strong> Solventum's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>0.67%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Solventum 在 3M 的卓越表现显而易见。截至 2025 年 9 月 30 日，该公司实现了 <strong>0.67%</strong> 的显著收入增长率。这标志着公司营业收入的显著增加。与医疗保健行业的其他公司相比，该公司面临挑战，增长率低于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>60.4%,</strong> the company showcases strong profitability and effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 该公司的净利润率表现突出，超过行业平均水平。凭借 <strong>60.4%</strong> 的净利润率，该公司展示了强大的盈利能力和有效的成本控制。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>29.34%,</strong> the company showcases effective utilization of equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 该公司的 ROE 表现突出，超过行业平均水平。凭借 <strong>29.34%</strong> 的 ROE，该公司展示了有效利用股本的能力。</p>
</div><p><strong>Return on Assets (ROA):</strong> Solventum's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>8.72%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Solventum 的财务实力体现在其卓越的 ROA 上，超过行业平均水平。凭借 <strong>8.72%</strong> 的 ROA，该公司展示了资产的高效使用和强大的财务健康。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.03</strong>, Solventum adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Solventum 的债务与股本比率低于平均水平，为 <strong>1.03</strong>，采取了谨慎的财务策略，表明了对债务管理的平衡方法。</p>
</div><h2>The Significance of Analyst Ratings Explained</h2>
<div class="lb-trans"><h2>分析师评级的重要性解释</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
</div><p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<div class="lb-trans"><p>分析师可能会补充他们的评级，预测增长估计、收益和收入等指标，为投资者提供更全面的前景。然而，投资者应注意，分析师和任何人一样，可能会受到主观观点的影响，从而影响他们的预测。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

分析师们对 Solventum 股票的评价